Laventair Ellipta

Umeclidinium bromide / Vilanterol, the active ingredients in Laventair Ellipta, are a Long‑acting muscarinic antagonist (LAMA) and Long‑acting β2‑agonist (LABA) combination presented as a 62.5 µg umeclidinium bromide / 25 µg vilanterol dry powder inhaler (Ellipta device) for inhalation use. It treats chronic obstructive pulmonary disease (COPD) and asthma as maintenance therapy in adults.

GNH USA supplies Laventair Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laventair Ellipta is indicated for maintenance bronchodilation in chronic airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves lung function, reduces exacerbation frequency, and enhances exercise tolerance. - Asthma (maintenance therapy): provides long‑term bronchodilation and helps achieve better symptom control. - Chronic bronchitis (as part of COPD): maintains airway patency and reduces cough severity.

Common Side Effects: - Cough or throat irritation: mild irritation after inhalation. - Headache: transient, often resolves without intervention. - Dry mouth: reduced salivation due to anticholinergic activity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Upper respiratory tract infection: mild viral‑like symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing requiring immediate medical attention. - Tachycardia or arrhythmia: rapid or irregular heart rhythm. - Severe hypersensitivity reactions: rash, swelling, or anaphylaxis. - Angioedema: swelling of lips, tongue, or throat. - Cardiovascular events: chest pain or myocardial ischemia in susceptible patients.

Before prescribing Laventair Ellipta, consider the following precautions: - Cardiovascular assessment: evaluate patients with known heart disease for potential tachycardia. - COPD severity monitoring: watch for worsening symptoms or frequent exacerbations. - History of paradoxical bronchospasm: avoid use if previously experienced. - Hepatic impairment: use with caution in severe liver disease. - Known hypersensitivity: do not administer to patients allergic to either component. - Store at room temperature: keep in original blister, protect from moisture and heat.

Laventair Ellipta may interact with other medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and increase risk of bronchospasm. - Other long‑acting muscarinic antagonists: additive anticholinergic effects can lead to dry mouth, urinary retention, or glaucoma.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate dry mouth and dehydration. - Theophylline: vilanterol can increase plasma theophylline levels, requiring dose adjustment. - Anticholinergic eye drops: may increase systemic anticholinergic load, leading to blurred vision or urinary retention.